By Larissa Dias
Emerging Oncology Trends for 2026: What Pharma and Biotech Need to Know
Oncology is continuously evolving. In 2026, innovation will accelerate even further, with AI-powered diagnostics, biomarker-driven therapies, rare tumor research, and patient-centric approaches reshaping the field.
But innovation alone isn’t enough. For pharma and biotech to stay ahead, they need insights that go beyond “what’s happening” to explain why it matters, and how stakeholders are responding in the real world.
Here are the five key oncology trends to watch in 2026, and why qualitative research is more important than ever in navigating them.
1. AI in Diagnostics and Decision Support
AI is transforming oncology, from imaging and pathology to treatment recommendations. But adoption depends on whether oncologists trust these tools, how payers assess value, and how patients perceive AI involvement in care. In-depth interviews and moderated discussions reveal these real-world perceptions, offering clarity beyond technical performance metrics.
2. Expansion of Biomarker-Driven Therapies
As biomarker pipelines expand, segmentation becomes more complex. For companies, this means ensuring their research covers niche subpopulations and captures physician decision-making at the biomarker level. Without qualitative insights, strategies risk being too generic for today’s precise oncology environment.
3. Rare and Niche Tumor Research
Investment in rare cancers is growing, from glioblastoma to pancreatic cancer. But rare doesn’t mean unreachable. With long-standing physician relationships and targeted recruitment strategies, Med Planet ensures these low-prevalence populations are represented in studies that influence product development and access.
4. Real-World Evidence Meets Qualitative Insight
RWE from registries, EHRs, and wearables is now central to oncology strategy. But numbers can’t explain why physicians adopt a therapy, or why patients abandon it. That’s where qualitative research complements RWE, adding context, emotion, and behavior to the data story.
5. Patient Experience as a Competitive Advantage
Patient journey insights are no longer “nice-to-have”. They are critical. Companies that understand treatment fatigue, caregiver burden, and emotional barriers can design support programs that truly make a difference. Qualitative methodologies like diaries and ethnographies bring these experiences to light.
Conclusion
Oncology in 2026 will be defined by precision, innovation, and patient-centered care. But navigating this complexity requires insights that are just as advanced as the therapies themselves.
At Med Planet, we specialise in qualitative oncology research that goes deeper: capturing the nuance, empathy, and context that pharma and biotech need to make confident decisions.
Why Med Planet?
At Med Planet, we specialise in custom recruitment, seamless logistics, and regulatory-compliant research execution. Many companies struggle with participant quotas and fail to deliver complete, reliable data, but we ensure every project is executed with precision and efficiency.
